

AMENDMENTS TO THE CLAIMS

Listing of Claims

The following listing of claims replaces all previous listings or versions thereof:

- 1-17. (Canceled)
18. (Currently amended) An antibody or antibody fragment being low or not immunogenic in humans and recognizing the human 17-1A antigen as expressed on the surface of tumor cells, the antibody or antibody fragment being further characterized as comprising a human VH chain and a human VL chain wherein at least said VH chain is a VH sequence of unprimed mature human B-lymphocytes and comprises three CDRs encoded by nucleotides 91 to 105, 148 to 198 and 292 to 351 within nucleotides 1 to 381 of SEQ ID NO: 143 and said VL chain is a VL sequence of a naturally occurring human B cell repertoire and comprises three CDRs encoded by nucleotides 70 to 102, 148 to 168 and 265 to 294 within nucleotides 1 to 321 of SEQ ID NO: 141.
19. (Previously presented) The antibody or antibody fragment according to claim 18, which is an antibody fragment.
- 20-30. (Canceled)
31. (Currently amended) The antibody or antibody fragment of claim ~~[[28]]~~18, recognizing an epitope of the extracellular domain of the 17-1A antigen.
32. (Currently amended) The antibody or antibody fragment of claim ~~[[28]]~~18, wherein ~~the said human~~ VH chain comprises the amino acid sequence encoded by nucleotides 1 to 381 of SEQ ID NO: 143 ~~or nucleotides 1 to 339 of SEQ ID NO: 145~~ and/or ~~the said human~~ VL chain comprises the amino acid sequence encoded by nucleotides 1-321 of SEQ ID NO: 141 ~~or nucleotides 1-321 of SEQ ID NO: 147.~~
- 33-37. (Canceled)

38. (Previously presented) A pharmaceutical composition comprising an antibody or antibody fragment according to claim 18, 65, 66 or 67, and a pharmaceutically acceptable carrier.
39. (Previously presented) A pharmaceutical composition comprising an antibody or antibody fragment according to claim 19, and a pharmaceutically acceptable carrier.
- 40-54. (Canceled)
55. (Previously presented) A pharmaceutical composition comprising an antibody or antibody fragment according to claim 31, and a pharmaceutically acceptable carrier.
56. (Previously presented) A pharmaceutical composition comprising an antibody or antibody fragment according to claim 32, and a pharmaceutically acceptable carrier.
- 57-64. (Canceled)
65. (Currently amended) The antibody or antibody fragment according to claim 18, further comprising, fused to said human VH and VL chains, ~~(a) the same or other VH or VL chains, (b)~~ immunoglobulin constant regions of heavy (CH) or light chains (CL) or parts thereof, or ~~(c)~~ non-immunoglobulin chains, respectively.
66. (Previously presented) The antibody or antibody fragment according to claim 65, wherein said constant region chains are from human IgG1 or IgG3.
67. (Currently amended) The antibody or antibody fragment according to claim 18, further comprising a non-~~proteinous~~proteinaceous pharmaceutical and/or other biologically active molecule linked to said human VH and VL chains.
68. (Canceled)